Chemokines and Their Receptors: Potential Therapeutic Targets for Bone Cancer Pain

Author(s): Ya-Qun Zhou, Heng-Yi Gao, Xue-Hai Guan, Xun Yuan, Guang-Guang Fang, Yuan Chen, Da-Wei Ye

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 34 , 2015

Become EABM
Become Reviewer
Call for Editor


Bone cancer pain (BCP) is still an intractable problem currently because the analgesic pharmacological intervention remains insufficient. Thus, the development of novel therapeutic target is critical for the treatment of BCP. Emerging evidence demonstrated that some chemokines and their receptors contribute to the induction and maintenance of BCP. In this article, we reviewed the current evidence for the role of different chemokines and their receptors (e.g. CXCL12/CXCR4, CXCL1/CXCR2, CCL2/CCR2, CCL5/CCR5, CX3CL1/CX3CR1 and CXCL10/CXCR3) in mediating BCP. By extensively understanding the involvement of chemokines and their receptors in BCP, novel therapeutic targets may be revealed for the treatment of BCP.

Keywords: Bone cancer pain, chemokine, chemokine receptor, therapeutic target.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 31 August, 2015
Page: [5029 - 5033]
Pages: 5
DOI: 10.2174/1381612821666150831141931
Price: $65

Article Metrics

PDF: 65